- ORAVIG® FEATURES – Once Daily Dosing, Flavorless, Odorless with an Innovative Buccal Delivery Technology.
- ORAVIG® is the First and Only Miconazole antifungal option available orally in a buccal tablet. ORAVIG® is indicated for the local treatment of oropharyngeal candidiasis in adults (OPC).
- It is estimated that millions of prescriptions are generated for antifungal products to treat OPC Praelia’s sales force commenced sales activity in Dec 2012.
- Product is now available for shipping.
- Praelia’s sales force of 100+ skilled reps is targeting high decile oncology supportive care physicians in all of the National Metro areas.
- Praelia will utilize a tele sales team to e-detail the physicians in the surrounding Metro areas nationally.
- Praelia is commitment to working closely with Managed Care partners to maximize reimbursement.
- Praelia is utilizing a discount copay card to reduce patient out of pocket cost.
- Praelia Pharmaceuticals has dedicated a vast amount of resources towards introducing Oravig.
NDC 43288-250-14 / Capital Wholesale Drug Co. order number 300200